

# YOU'RE INVITED

## 2023 ABSSSI Deck - An Effective, Broad-Spectrum Antibiotic For The Treatment of ABSSSI in Adults

Please join us for an engaging program to learn more about a treatment option approved by the US Food and Drug Administration (FDA).

Please see complete Indications and Important Safety Information below.



once-daily  
**NUZYRA**<sup>®</sup>  
(omadacycline)

100 mg for injection / 150 mg tablets

**Thursday, September 21, 2023**

The Old Homestead  
Steakhouse  
56 9th Ave  
New York, NY 10011

### PROGRAM AGENDA

Registration  
7:00 PM EST

Presentation  
7:30 PM EST

### HOSTED BY

Branden Suarez - PSS  
(201) 212-7234

### PRESENTED BY

Evan Cichelli, DPM  
Podiatric Surgery  
Lansdale Hospital PA

To register for this event, please visit [www.paratekportal.com/registration](http://www.paratekportal.com/registration) and enter the event code below.

**Event Code: 2484**

**Please RSVP by  
Tuesday, September 19<sup>th</sup>**

#### INDICATIONS AND USAGE

NUZYRA is a tetracycline-class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms:

**Community-Acquired Bacterial Pneumonia (CABP) caused by the following:** *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible isolates), *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Mycoplasma pneumoniae*, and *Chlamydia pneumoniae*.  
**Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by the following:**

*Staphylococcus aureus* (methicillin-susceptible and -resistant isolates), *Staphylococcus lugdunensis*, *Streptococcus pyogenes*, *Streptococcus anginosus* grp. (includes *S. anginosus*, *S. intermedius*, and *S. constellatus*), *Enterococcus faecalis*, *Enterobacter cloacae*, and *Klebsiella pneumoniae*.

#### USAGE

To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

#### IMPORTANT SAFETY INFORMATION

##### CONTRAINDICATIONS

NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline-class antibacterial drugs, or to any of the excipients.

##### WARNINGS AND PRECAUTIONS

In the CABP trial, a 2% mortality rate (8 deaths) was observed in NUZYRA-treated patients compared to 1% (4 deaths) in moxifloxacin-treated patients. All deaths, in both

This is a promotional program and no CME credits are offered. Paratek Pharmaceuticals, Inc. complies with all Federal and State Transparency Laws; if you are a Healthcare Professional, please be aware that any transfer of value provided to you by Paratek may be reported under applicable laws and regulations.

Attendees are not permitted to attend this program more than 2 times in the calendar year.

treatment arms, occurred in patients > 65 years of age; most patients had multiple comorbidities. The cause of the mortality imbalance has not been established. Closely monitor clinical response to therapy in CABP patients, particularly in those at higher risk for mortality.

The use of NUZYRA during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. The use of NUZYRA during the second and third trimester of pregnancy, infancy, and childhood up to the age of 8 years may cause reversible inhibition of bone growth. Evaluate patients for *Clostridioides difficile* associated diarrhea if diarrhea occurs. NUZYRA is structurally similar to other tetracycline-class antibacterial drugs and may have similar adverse reactions, including: life-threatening anaphylactic reactions, photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests). Discontinue NUZYRA if any of these adverse reactions are suspected.

#### ADVERSE REACTIONS

The most common adverse reactions (incidence  $\geq 2\%$ ) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation.

**Please see accompanying Full Prescribing Information.**



**PARATEK**

© 2021 Paratek Pharmaceuticals, Inc. All rights reserved.

PARATEK<sup>®</sup> and the hexagon logo are registered trademarks of Paratek Pharmaceuticals, Inc. NUZYRA<sup>®</sup> and its design logo are registered trademarks of Paratek Pharmaceuticals, Inc. US-NUA-0596 05/22